Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MATCHSTICK TECHNOLOGIES INC
- Proposal award date
- 2017-09-01
- Contract end date
- 2019-08-31
- UEI
- GEY3HA4ZT4C7
- Solicitation number
- PA16-302
- Topic code
- 400
Research abstract
Several types of cancerse gpancreatic and brain malignanciesremain extremely lethal despite the
introduction of chemotherapy more thanyears agoThe hallmark of all cancers are somatic mutations which
cannot be correctedIn sharp contrastepigenetic changesessential contributors to tumorigenesisare
pharmacologically reversibleThe ability to remedy detrimental epigenetic alterations are opening up new
treatment avenuesGlioblastoma is an example where an epigenetic mark guides treatmentIn epigeneticsthe
Chromatin ImmunoPrecipitationChIPassay is used to determine the genomic location of a given protein and
its modification se ghistonestranscription factors or epigenetic modifying enzymesThe assay requires
small samples of chromatin or DNA be fragmented reproduciblywithout contamination or sample degradationUnfortunatelycurrent technologies suffer from epitope loss and irreproducibility due to time consuming and
inconsistent shearingmaking the ChIP assay unreliable for clinical useWe have overcome this bottleneck with
PIXULPIXelated ULtrasoundThe device uses ultrasound transducers that treat samples equally in every well
of awell microplateAll samples are processed simultaneously and reproducibly in a few minutesa minimumx improvement over existing technologiesWith PIXULcells are grown inwell microplatesand then crosslinked and harvested in situminand sheared inminutesSimilarlydozens of tissue samples can also be
quickly processed in parallelall in one microplatefor e gtoxicity studiesNo other commercial system is
capable of thisThe prepared microplate may further be used directly in the assayeliminating the need for time
consuming manual transfer stepsPIXUL is automated and requires little trainingOur workflow breakthrough is
a major step towards fast and accurate assayscritically important for drug discovery and personalized
medicinemaking PIXUL a valuable sample preparation tool in epigeneticsand also in NGS and potentially a
variety of other analytical applicationse gproteomicsmetabolomicsWe have excellent results with our
current lab prototypeChIP qPCR and ChIP Seq resultsand ChIP assay signals are stronger and more
reproducible than from commercial competitorsThe overarching goal of this project is to advance PIXUL to a
commercial prototype for end user evaluation and feedbackTwo Aims are proposedIn Aimwe will develop
a custom microplate that will decrease shearing time and heat generationThe main goal here is maximize
epitope integrityIn Aimwe will fabricate commercial prototype PIXUL devices for evaluation and feedbackThis information will be used to manufacture market ready PIXUL instrumentMajor epigenetic companies have
stated that PIXUL is a game changer and expressed interest in partnering with us to market it
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
4 SBIR/STTR records share this UEI (2017–2020). Reported award amounts total $4,682,028. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards